
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7948115/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Coagulopathy of Chronic Liver Disease. New England Journal of Medicine, 2011, 365, 147-156.	13.9	1,171
2	Hypercoagulability of COVIDâ€19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 1738-1742.	1.9	1,070
3	Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology, 2005, 41, 553-558.	3.6	617
4	d-Dimer Testing to Determine the Duration of Anticoagulation Therapy. New England Journal of Medicine, 2006, 355, 1780-1789.	13.9	593
5	An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis. Gastroenterology, 2009, 137, 2105-2111.	0.6	472
6	Thrombin generation in patients with cirrhosis: The role of platelets. Hepatology, 2006, 44, 440-445.	3.6	347
7	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion, 2020, 18, 167-169.	0.3	247
8	Thrombin Generation Assay and Its Application in the Clinical Laboratory. Clinical Chemistry, 2016, 62, 699-707.	1.5	241
9	Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology, 2019, 156, 1582-1599.e1.	0.6	230
10	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2828-2839.	1.9	211
11	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood, 2004, 104, 3631-3634.	0.6	179
12	The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology, 2007, 46, 520-527.	3.6	179
13	Abnormalities of hemostasis in chronic liver disease: Reappraisal of their clinical significance and need for clinical and laboratory research. Journal of Hepatology, 2007, 46, 727-733.	1.8	166
14	Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation Thrombosis and Haemostasis, 2011, 106, 868-876.	1.8	158
15	d-Dimer Testing in Laboratory Practice. Clinical Chemistry, 2011, 57, 1256-1262.	1.5	157
16	The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thrombosis Research, 2009, 124, 132-136.	0.8	155
17	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	1.8	149
18	Changing Concepts of Cirrhotic Coagulopathy. American Journal of Gastroenterology, 2017, 112, 274-281.	0.2	149

#	Article	IF	CITATIONS
19	Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. Journal of Hepatology, 2013, 59, 265-270.	1.8	146
20	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thrombosis Research, 2016, 137, 178-183.	0.8	141
21	Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica, 2003, 88, 547-54.	1.7	140
22	Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. Journal of Thrombosis and Thrombolysis, 2011, 31, 165-172.	1.0	129
23	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology, 2010, 52, 249-255.	3.6	123
24	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2017, 66, 248-250.	1.8	123
25	Laboratory Investigation of Thrombophilia. Clinical Chemistry, 2001, 47, 1597-1606.	1.5	116
26	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver International, 2013, 33, 362-367.	1.9	107
27	Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. British Journal of Haematology, 2009, 147, 77-82.	1.2	105
28	The laboratory and the direct oral anticoagulants. Blood, 2013, 121, 4032-4035.	0.6	97
29	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Internal and Emergency Medicine, 2012, 7, 139-144.	1.0	96
30	Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio?. Thrombosis and Haemostasis, 1993, 70, 0921-0924.	1.8	93
31	Circulating microparticles and risk of venous thromboembolism. Thrombosis Research, 2012, 129, 591-597.	0.8	92
32	Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. British Journal of Haematology, 2001, 115, 672-678.	1.2	84
33	Antiphospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-β2-Glycoprotein I activity. Thrombosis Research, 2007, 120, 127-133.	0.8	77
34	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1146-1152.e4.	2.4	77
35	Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 1569-1575.	1.9	76
36	Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica, 2009, 94, 1520-1527.	1.7	74

#	Article	IF	CITATIONS
37	The endogenous thrombin potential and the risk of venous thromboembolism. Thrombosis Research, 2007, 121, 353-359.	0.8	73
38	Lupus Anticoagulant (LA) Testing: Performance of Clinical Laboratories Assessed by a National Survey Using Lyophilized Affinity-purified Immunoglobulin with LA Activity. Clinical Chemistry, 2003, 49, 1608-1614.	1.5	70
39	Unbalanced oxidative status in idiopathic sudden sensorineural hearing loss. European Archives of Oto-Rhino-Laryngology, 2012, 269, 449-453.	0.8	70
40	Laboratory Testing for Lupus Anticoagulants: A Review of Issues Affecting Results. Clinical Chemistry, 2007, 53, 1629-1635.	1.5	68
41	Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. Journal of Hepatology, 2020, 72, 85-94.	1.8	68
42	Laboratory Screening of Inherited Thrombotic Syndromes. Thrombosis and Haemostasis, 1987, 57, 247-251.	1.8	67
43	Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests. Haematologica, 2008, 93, 1256-1259.	1.7	66
44	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 1116-1122.	1.9	66
45	Laboratory Diagnosis of Lupus Anticoagulants for Patients on Oral Anticoagulant Treatment. Thrombosis and Haemostasis, 2002, 88, 583-586.	1.8	64
46	Increased thrombin generation in inflammatory bowel diseases. Thrombosis Research, 2010, 125, 278-282.	0.8	61
47	The Laboratory and the New Oral Anticoagulants. Clinical Chemistry, 2013, 59, 353-362.	1.5	60
48	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, 6, 1534-1541.	1.9	57
49	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	57
50	Hemostasis abnormalities in cirrhosis. Current Opinion in Hematology, 2015, 22, 406-412.	1.2	55
51	Screening for the FV: Q506 Mutation – Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis. Thrombosis and Haemostasis, 1997, 77, 436-439.	1.8	55
52	Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thrombosis Research, 1992, 67, 355-365.	0.8	54
53	International Collaborative Study for the Calibration of a Proposed Reference Preparation for Thromboplastin, Human Recombinant, Plain. Thrombosis and Haemostasis, 1998, 79, 439-443.	1.8	54
54	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfusion, 2018, 16, 462-470.	0.3	54

#	Article	IF	CITATIONS
55	Multicenter Study of Homocysteine Measurement – Performance Characteristics of Different Methods, Influence of Standards on Interlaboratory Agreement of Results. Thrombosis and Haemostasis, 2001, 85, 291-295.	1.8	53
56	Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Internal and Emergency Medicine, 2010, 5, 7-12.	1.0	53
57	Resistance to thrombomodulin is associated with <i>de novo</i> portal vein thrombosis and low survival in patients with cirrhosis. Liver International, 2016, 36, 1322-1330.	1.9	51
58	Hemostatic defects in liver and renal dysfunction. Hematology American Society of Hematology Education Program, 2012, 2012, 168-173.	0.9	48
59	Tests of Coagulation in Liver Disease. Clinics in Liver Disease, 2009, 13, 55-61.	1.0	47
60	Lupus Anticoagulants and Their Relationship with the Inhibitors against Coagulation Factor VIII: Considerations on the Differentiation between the 2 Circulating Anticoagulants. Clinical Chemistry, 2005, 51, 1883-1885.	1.5	44
61	A Comparison of Lupus Anticoagulant–Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, e309-10.	1.1	43
62	Near-patient testing devices to monitor oral anticoagulant therapy. British Journal of Haematology, 2001, 113, 847-852.	1.2	41
63	Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern. Thrombosis and Haemostasis, 2002, 88, 690-691.	1.8	41
64	Liver Disease and Hemostatic (Dys)function. Seminars in Thrombosis and Hemostasis, 2015, 41, 462-467.	1.5	41
65	Assessment of the Influence of Citrate Concentration on the International Normalized Ratio (INR) Determined with Twelve Reagent-instrument Combinations. Thrombosis and Haemostasis, 1998, 80, 258-262.	1.8	40
66	Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods. BMJ: British Medical Journal, 2003, 327, 30-0.	2.4	40
67	Extracellular vesicle-driven information mediates the long-term effects of particulate matter exposure on coagulation and inflammation pathways. Toxicology Letters, 2016, 259, 143-150.	0.4	39
68	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 39-47.	1.9	39
69	How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters. Thrombosis Research, 2015, 135, 1186-1190.	0.8	38
70	D-dimer testing for suspected venous thromboembolism in the emergency department. Consensus document of AcEMC, CISMEL, SIBioC, and SIMeL. Clinical Chemistry and Laboratory Medicine, 2014, 52, 621-8.	1.4	37
71	A Review of the Clinical and Diagnostic Utility of Laboratory Tests for the Detection of Congenital Thrombophilia. Seminars in Thrombosis and Hemostasis, 2005, 31, 25-32.	1.5	36
72	To Mix or Not to Mix in Lupus Anticoagulant Testing? That is the Question. Seminars in Thrombosis and Hemostasis, 2012, 38, 385-389.	1.5	35

#	Article	IF	CITATIONS
73	Detection of procoagulant imbalance. Thrombosis and Haemostasis, 2017, 117, 830-836.	1.8	35
74	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica, 2018, 103, e315-e317.	1.7	34
75	Hemostatic alterations in COVID-19. Haematologica, 2021, 106, 1472-1475.	1.7	34
76	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency. Pediatrics, 2013, 132, e1435-e1439.	1.0	33
77	A National Field Study of Quality Assessment of CoaguChek Point-of-Care Testing Prothrombin Time Monitors. American Journal of Clinical Pathology, 2006, 126, 756-761.	0.4	32
78	Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 1372-1378.	1.9	32
79	Laboratory Testing for Lupus Anticoagulants: Diagnostic Criteria and Use of Screening, Mixing, and Confirmatory Studies. Seminars in Thrombosis and Hemostasis, 2008, 34, 373-379.	1.5	30
80	Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. Haematologica, 2008, 93, 900-907.	1.7	30
81	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20Âyears ago. Internal and Emergency Medicine, 2017, 12, 1109-1119.	1.0	30
82	The coagulopathy of chronic liver disease: Is there a causal relationship with bleeding? No. European Journal of Internal Medicine, 2010, 21, 65-69.	1.0	29
83	Hemostasis in Acute and Chronic Liver Disease. Seminars in Liver Disease, 2017, 37, 028-032.	1.8	29
84	Hyperprothrombinemia may result in acquired activated protein C resistance. Blood, 2000, 96, 3295-3296.	0.6	28
85	A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thrombosis Research, 2009, 124, 137-143.	0.8	28
86	How to evaluate the influence of blood collection systems on the international sensitivity index. Protocol applied to two new evacuated tubes and eight coagulometer/thromboplastin combinations. Thrombosis Research, 2002, 108, 85-89.	0.8	27
87	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Internal and Emergency Medicine, 2018, 13, 1029-1036.	1.0	27
88	Levels of coagulation factors and venous thromboembolism. Haematologica, 2003, 88, 705-11.	1.7	27
89	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. Journal of Hepatology, 2009, 51, 288-295.	1.8	26
90	Global coagulation in myeloproliferative neoplasms. Annals of Hematology, 2013, 92, 1633-1639.	0.8	26

#	Article	IF	CITATIONS
91	Liver disease, coagulopathies and transfusion therapy. Blood Transfusion, 2013, 11, 32-6.	0.3	26
92	Calibration of Local Systems with Lyophilized Calibrant Plasmas Improves the Interlaboratory Variability of the INR in the Italian External Quality Assessment Scheme. Thrombosis and Haemostasis, 1999, 82, 1621-1626.	1.8	25
93	Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy. Thrombosis and Haemostasis, 1997, 78, 855-858.	1.8	25
94	European Concerted Action on Anticoagulation. Use of Plasma Samples to Derive International Sensitivity Index for Whole-Blood Prothrombin Time Monitors. Clinical Chemistry, 2002, 48, 255-260.	1.5	24
95	Laboratory Monitoring of Anticoagulation: Where Do We Stand?. Seminars in Thrombosis and Hemostasis, 2009, 35, 034-041.	1.5	24
96	Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus Medicine, 2012, 50, 2137-2140.	1.4	23
97	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. Clinical Chemistry, 2019, 65, 254-262.	1.5	23
98	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. Endocrine, 2017, 56, 298-307.	1.1	22
99	European Concerted Action on Anticoagulation. American Journal of Clinical Pathology, 2003, 119, 232-240.	0.4	21
100	European Concerted Action on Anticoagulation. Quality Assessment of the CoaguChek Mini and TAS PT-NC Point-of-Care Whole-Blood Prothrombin Time Monitors. Clinical Chemistry, 2004, 50, 537-544.	1.5	20
101	Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant. Thrombosis and Haemostasis, 2013, 110, 46-52.	1.8	20
102	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Digestive and Liver Disease, 2016, 48, 1208-1213.	0.4	20
103	Critical laboratory values in hemostasis: toward consensus. Annals of Medicine, 2017, 49, 455-461.	1.5	20
104	Standardization of the endogenous thrombin potential measurement: how to minimize the effect of residual platelets in stored plasma. British Journal of Haematology, 2004, 124, 355-357.	1.2	19
105	How to report results of prothrombin and activated partial thromboplastin times. Clinical Chemistry and Laboratory Medicine, 2016, 54, 215-22.	1.4	19
106	Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test. Thrombosis and Haemostasis, 1992, 67, 042-045.	1.8	19
107	Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?. Thrombosis and Haemostasis, 2011, 105, 735-736.	1.8	18
108	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver International, 2017, 37, 1295-1303.	1.9	18

#	Article	IF	CITATIONS
109	Quality assurance program for whole blood prothrombin time–international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation. Thrombosis Research, 2004, 113, 35-40.	0.8	17
110	Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2010, 30, 215-219.	1.0	17
111	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia, 2020, 26, 937-945.	1.0	17
112	Thromboelastographic profiles of healthy very low birthweight infants serially during their first month. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2020, 105, 412-418.	1.4	17
113	Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thrombosis and Haemostasis, 2002, 88, 583-6.	1.8	17
114	Standardization of the APC Resistance Test. Effects of Normalization of Results by Means of Pooled Normal Plasma. Thrombosis and Haemostasis, 1998, 79, 564-566.	1.8	16
115	The History of Phenotypic Testing in Thrombosis and Hemostasis. Seminars in Thrombosis and Hemostasis, 2008, 34, 585-592.	1.5	16
116	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines, 2022, 10, 249.	1.4	16
117	Laboratory Diagnosis of Lupus Anticoagulants. Thrombosis and Haemostasis, 2002, 87, 854-858.	1.8	15
118	How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Clinical Chemistry and Laboratory Medicine, 2015, 53, 265-73.	1.4	15
119	Unexpected, isolated activated partial thromboplastin time prolongation: A practical miniâ€review. European Journal of Haematology, 2020, 104, 519-525.	1.1	15
120	Statins decrease thrombin generation in patients with hypercholesterolemia. European Journal of Internal Medicine, 2014, 25, 449-451.	1.0	14
121	European Concerted Action on Anticoagulation. Evaluation of a Method for International Sensitivity Index Calibration of Two Point-of-Care Prothrombin Time (PT) Monitoring Systems (CoaguChek Mini) Tj ETQq1 1 1672-1680.	0.784314 1.5	rgBT /Overlo
122	Issues Concerning the Laboratory Investigation of Inherited Thrombophilia. Molecular Diagnosis and Therapy, 2005, 9, 181-186.	1.3	13
123	Performance of Clinical Laboratories for DNA Analyses to Detect Thrombophilia Mutations. Clinical Chemistry, 2005, 51, 1310-1311.	1.5	13
124	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. International Journal of Hematology, 2016, 103, 165-172.	0.7	13
125	The intra-assay reproducibility of thromboelastography in very low birth weight infants. Early Human Development, 2018, 127, 48-52.	0.8	13
126	How to implement the modified international normalized ratio for cirrhosis (INRliver) for model for end-stage liver disease calculation. Hepatology, 2008, 47, 1423-1424.	3.6	12

#	Article	IF	CITATIONS
127	Problems and Solutions for Testing Hemostasis Assays while Patients Are on Anticoagulants. Seminars in Thrombosis and Hemostasis, 2012, 38, 586-592.	1.5	12
128	The Long-Awaited Whole-Blood Thrombin Generation Test. Clinical Chemistry, 2012, 58, 1173-1175.	1.5	12
129	Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. Thrombosis Research, 2020, 185, 96-101.	0.8	12
130	Prothrombin time international normalized ratio monitoring by self-testing. Current Opinion in Hematology, 2004, 11, 141-145.	1.2	11
131	Laboratory tests and the new oral anticoagulants. Thrombosis Research, 2012, 130, S95-S97.	0.8	11
132	Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia. Hepatology, 2013, 58, 1177-1180.	3.6	11
133	Lupus Anticoagulant Testing: Activated Partial Thromboplastin Time (APTT) and Silica Clotting Time (SCT). Methods in Molecular Biology, 2017, 1646, 177-183.	0.4	11
134	Usefulness of Thrombin Generation. Hamostaseologie, 2020, 40, 509-514.	0.9	11
135	Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth?. Transfusion, 2020, 60, 1069-1077.	0.8	11
136	Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. Thrombosis Research, 2021, 204, 32-39.	0.8	11
137	Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 365-371.	1.4	11
138	Factor VIII Activity as Measured by an Amidolytic Assay Compared with a One-Stage Clotting Assay. American Journal of Clinical Pathology, 1986, 86, 341-344.	0.4	10
139	Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability. Haematologica, 2020, 105, 2196-2199.	1.7	10
140	International Sensitivity Index Calibration of the Near-Patient Testing Prothrombin Time Monitor, ProTime. American Journal of Clinical Pathology, 2003, 119, 241-245.	0.4	9
141	Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. Thrombosis Research, 2014, 133, 1130-1134.	0.8	9
142	Alpha2-Macroglobulin Levels Are High in Adult Patients with Congenital Antithrombin Deficiency. Thrombosis Research, 2000, 98, 117-122.	0.8	8
143	Laboratory diagnosis of thrombophilic states: where do we stand?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 245-248.	0.5	8
144	Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home-made methods. British Journal of Haematology, 2003, 120, 825-828.	1.2	8

#	Article	lF	CITATIONS
145	Pro-coagulant imbalance in patients with chronic liver disease. Journal of Hepatology, 2010, 53, 586-587.	1.8	8
146	Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. Thrombosis Research, 2011, 127, 589-594.	0.8	8
147	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver International, 2019, 39, 2309-2316.	1.9	8
148	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. Journal of Thrombosis and Thrombolysis, 2019, 48, 52-60.	1.0	8
149	Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. Haematologica, 2021, 106, 3021-3024.	1.7	8
150	Haemostasis Abnormalities in Chronic Liver Failure. , 2011, , 289-303.		7
151	Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants. Thrombosis Journal, 2013, 11, 9.	0.9	7
152	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1660-e1672.	1.8	7
153	Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia. Cells, 2022, 11, 1148.	1.8	7
154	Interference of new oral anticoagulants with frequently used coagulation tests. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1501-3.	1.4	6
155	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2020, 18, 3117-3118.	1.9	6
156	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET). Journal of Nephrology, 2021, 34, 31-38.	0.9	6
157	No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2. Thrombosis Update, 2021, 4, 100059.	0.4	6
158	Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations–a cause for concern. Thrombosis and Haemostasis, 2002, 88, 690-1.	1.8	6
159	Reply to: Endogenous heparinoids contribute to coagulopathy in patients with liver disease. Journal of Hepatology, 2008, 48, 372-373.	1.8	5
160	A(nother) Test Meant to Fill the Gap between In Vivo and Ex Vivo Hemostasis. Clinical Chemistry, 2014, 60, 1137-1140.	1.5	5
161	Periprocedural management of rivaroxaban-treated patients. Expert Opinion on Pharmacotherapy, 2015, 16, 685-691.	0.9	5
162	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. Vascular Pharmacology, 2019, 113, 92-93.	1.0	5

#	Article	IF	CITATIONS
163	Anti-TNF-α Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 1901-1908.	0.9	5
164	Diagnostic Challenges on the Laboratory Detection of Lupus Anticoagulant. Biomedicines, 2021, 9, 844.	1.4	5
165	Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding Blood Transfusion, 2022, , .	0.3	5
166	Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay. Blood Coagulation and Fibrinolysis, 2007, 18, 543-546.	0.5	4
167	The validity of the INR system for patients with liver disease. Journal of Thrombosis and Thrombolysis, 2011, 31, 209-210.	1.0	4
168	Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis. Journal of Hepatology, 2015, 63, 277-278.	1.8	4
169	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. Thrombosis Research, 2019, 174, 84-87.	0.8	4
170	Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. Frontiers in Pediatrics, 2020, 8, 510.	0.9	4
171	Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. Thrombosis Research, 2020, 190, 20-25.	0.8	4
172	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion, 2021, 19, 14-23.	0.3	4
173	Comments on: Laboratory tests for the management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants: Proposals of the Working Group on Perioperative Haemostasis (GIHP). Archives of Cardiovascular Diseases, 2014, 107, 345-346.	0.7	3
174	Relationship between thrombin generation parameters and prothrombin fragment 1Â+Â2 plasma levels. International Journal of Laboratory Hematology, 2021, 43, e248-e251.	0.7	3
175	Hemostasis abnormalities in liver cirrhosis: myth or reality?. , 2008, 118, 445-8.		3
176	Laboratory tests during direct oral anticoagulant treatment. Internal and Emergency Medicine, 2014, 9, 903-905.	1.0	2
177	Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. Journal of Thrombosis and Thrombolysis, 2020, 49, 413-419.	1.0	2
178	Letter to the Editor: Thromboelastographyâ€Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?. Hepatology, 2020, 72, 1158-1159.	3.6	2
179	Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study. International Journal of Laboratory Hematology, 2020, 42, e128-e131.	0.7	2
180	Issues Concerning the Laboratory Investigation of Inherited Thrombophilia. , 2005, 9, 181.		2

11

ARMANDO TRIPODI

#	Article	IF	CITATIONS
181	Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial". Blood Transfusion, 2020, 18, 239-240.	0.3	2
182	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. Blood Transfusion, 2020, 18, 478-485.	0.3	2
183	Management of special conditions in patients on vitamin K antagonists. Internal and Emergency Medicine, 2012, 7, 407-413.	1.0	1
184	Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1699-1708.	1.4	1
185	Thrombin Generation in Severe Hemophiliacs with Different Clinical Phenotype Blood, 2006, 108, 1000-1000.	0.6	1
186	Cirrhosis. What are all those factor VIII and protein C for?. Journal of Hepatology, 2022, , .	1.8	1
187	Reply to: Is platelet transfusion necessary in cirrhotic patients with splenomegaly?. Liver International, 2014, 34, 478-479.	1.9	Ο
188	Commentary. Clinical Chemistry, 2017, 63, 1445-1446.	1.5	0
189	Response to Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy Liver International, 2018, 38, 186-186.	1.9	0
190	Should We Be Concerned About Coagulation in the Treatment of Acute Variceal Hemorrhage?. , 2014, , 203-210.		0
191	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. Vascular Pharmacology, 2022, 144, 106994.	1.0	Ο
192	Impact of a commercially available <scp>DOAC</scp> absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0